纠正神经髓炎光学诊断和治疗的全球不平等
1Department of Neurology, Massachusetts General Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA.
概括
视神经炎 (NMO) 护理在世界各地是不平等的. 本次审查提出了九个目标,以改善全球的NMO诊断和治疗,强调其在没有预防性免疫抑制治疗的情况下的致残和致命潜力.
科学领域:
- 神经免疫学 神经免疫学
- 神经学 神经学
- 全球健康 全球健康
背景情况:
- 光学神经炎 (NMO) 是一种严重的自身免疫性疾病,影响中枢神经系统.
- 在NMO患者的护理标准方面,全球存在显著的差异.
- 如果不治疗,NMO可能会导致残疾和死亡,需要免疫抑制治疗.
研究的目的:
- 突出在NMO诊断和治疗方面的全球不平等.
- 倡导将NMO视为高死亡率疾病的看法重新定义.
- 提出一个框架来解决这些全球差异.
主要方法:
- 关于NMO流行,影响和治疗的已公布数据的审查.
- 对当前全球护理和治疗准入标准的分析.
- 基于疾病特征和现有的公共卫生模型制定集体目标.
主要成果:
- 为了防止残疾和死亡,NMO需要及时接受免疫抑制治疗.
- 自2019年以来,多种疾病修饰疗法 (DMT) 已被批准用于水素-4抗体血清阳性NMO.
- 在获得诊断和有效治疗方面,全球仍然存在重大不平等.
结论:
- 在全球范围内,NMO应该被认为是一种可治疗但可能致命的疾病.
- 类似于癌症或艾滋病毒/艾滋病的公共卫生策略是NMO的必要条件.
- 九个拟议的目标旨在纠正NMO管理中的全球不平等,并改善患者的治疗结果.
相关概念视频
Open Angle Glaucoma: Treatment
491
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
491
Angle Closure Glaucoma: Treatment
578
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
578
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K


